119 related articles for article (PubMed ID: 36798261)
21. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
[TBL] [Abstract][Full Text] [Related]
22. High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Leuk Lymphoma; 2006 Aug; 47(8):1545-52. PubMed ID: 16966265
[TBL] [Abstract][Full Text] [Related]
23. Predictive value of [¹⁸F]fluoro-2-deoxy-D-glucose positron emission tomography for clinical outcome in patients with relapsed/refractory diffuse large B-cell lymphoma prior to and after autologous stem cell transplant.
Qiao W; Zhao J; Xing Y; Wang C; Wang T
Leuk Lymphoma; 2014 Feb; 55(2):276-82. PubMed ID: 23617323
[TBL] [Abstract][Full Text] [Related]
24. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
Alkhaldi H; Reinhardt A; Barnett M; Kundu S; Hosing C; Ramdial J; Saini N; Srour S; Alousi A; Kebriaei P; Popat U; Qazilbash M; Champlin R; Shpall EJ; Gulbis A; Shigle TL; Dabaja B; Pinnix C; Ahmed S; Steiner R; Andersson BS; Nieto Y
Transplant Cell Ther; 2023 Nov; 29(11):690-694. PubMed ID: 37607645
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of autologous transplant with non-cryopreserved peripheral blood stem cells in myeloma and lymphoma in Algeria. 10 years' experience.
Bekadja MA; Entasoltan B; Amani K; Ouldjeriouat H; Osmani S; Bouchama S; Charef L; Arabi A; Brahimi M; Bouhass AR; Yafour N
Tunis Med; 2022 Novembre; 100(11):762-768. PubMed ID: 37551517
[TBL] [Abstract][Full Text] [Related]
26. Impact of Risk Factors and Long Term Survival Analysis of Patients With Primary Refractory Hodgkin Lymphoma Who Underwent High Dose Chemotherapy and Autologous Stem Cell Transplant.
Akhtar S; Rauf MS; Elhassan TAM; Khan ZA; Elshenawy MA; Maghfoor I
Transplant Cell Ther; 2023 Jul; 29(7):451.e1-451.e12. PubMed ID: 37031748
[TBL] [Abstract][Full Text] [Related]
27. The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis.
Wullenkord R; Berning P; Niemann AL; Wethmar K; Bergmann S; Lutz M; Schliemann C; Mesters R; Keßler T; Schmitz N; Berdel WE; Lenz G; Stelljes M
Ann Hematol; 2021 Nov; 100(11):2733-2744. PubMed ID: 34477953
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of Older Adults with Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation: A Mayo Clinic Cohort Analysis.
Wudhikarn K; Johnson BM; Inwards DJ; Porrata LF; Micallef IN; Ansell SM; Hogan WJ; Paludo J; Villasboas JC; Johnston PB
Transplant Cell Ther; 2023 Mar; 29(3):176.e1-176.e8. PubMed ID: 36563788
[TBL] [Abstract][Full Text] [Related]
29. Chimeric antigen receptor T-cell therapy combined with autologous stem cell transplantation improved progression-free survival of relapsed or refractory diffuse large B-cell lymphoma patients: A single-center, retrospective, cohort study.
Wang T; Xu L; Gao L; Tang G; Chen L; Chen J; Wang Y; Fu W; Yue W; Ye M; Yu J; Yu X; Feng D; Zhang A; Yang J
Hematol Oncol; 2022 Oct; 40(4):637-644. PubMed ID: 35141937
[TBL] [Abstract][Full Text] [Related]
30. Comparation of CART19 and autologous stem-cell transplantation for refractory/relapsed non-Hodgkin's lymphoma.
Li C; Zhang Y; Zhang C; Chen J; Lou X; Chen X; Kang L; Xu N; Li M; Tan J; Sun X; Zhou J; Yang Z; Zong X; Wang P; Xu T; Qu C; Huang H; Jin Z; Yu L; Wu D
JCI Insight; 2019 Jul; 5(17):. PubMed ID: 31335321
[TBL] [Abstract][Full Text] [Related]
31. Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the phase III CCTG LY.12 trial.
Davison K; Chen BE; Kukreti V; Couban S; Benger A; Berinstein NL; Kaizer L; Desjardins P; Mangel J; Zhu L; Djurfeldt MS; Hay AE; Shepherd LE; Crump M
Ann Oncol; 2017 Mar; 28(3):622-627. PubMed ID: 27993811
[TBL] [Abstract][Full Text] [Related]
32. Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Vose JM; Habermann TM; Czuczman MS; Zinzani PL; Reeder CB; Tuscano JM; Lossos IS; Li J; Pietronigro D; Witzig TE
Br J Haematol; 2013 Sep; 162(5):639-47. PubMed ID: 23834234
[TBL] [Abstract][Full Text] [Related]
33. Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation.
Giulino-Roth L; Ricafort R; Kernan NA; Small TN; Trippett TM; Steinherz PG; Prockop SE; Scaradavou A; Chiu M; O'Reilly RJ; Boulad F
Pediatr Blood Cancer; 2013 Dec; 60(12):2018-24. PubMed ID: 24038967
[TBL] [Abstract][Full Text] [Related]
34. First-line high-dose therapy and autologous blood stem cell transplantation in patients with primary central nervous system non-Hodgkin lymphomas-a single-centre experience in 61 patients.
Brezina T; von Dewitz H; Schroeder T; Ullrich S; Nachtkamp K; Reifenberger G; Malzkorn B; Sabel M; Haas R; Kobbe G
Ann Hematol; 2022 Mar; 101(3):607-616. PubMed ID: 34982196
[TBL] [Abstract][Full Text] [Related]
35. The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase.
Kim YR; Kim SJ; Cheong JW; Yang DH; Lee H; Eom HS; Sung YO; Kim HJ; Kang HJ; Lee WS; Park Y; Yang WI; Min YH; Kim JS
Ann Hematol; 2016 Sep; 95(9):1491-501. PubMed ID: 27324387
[TBL] [Abstract][Full Text] [Related]
36. Are dynamic or fixed FDG-PET measures of disease of greater prognostic value in patients with relapsed/refractory diffuse large B-cell lymphoma undergoing autologous haematopoietic stem cell transplantation?
Campbell BA; Brown R; Lambertini A; Hofman MS; Bressel M; Seymour JF; Wirth A; MacManus M; Dickinson M
Br J Haematol; 2023 May; 201(3):502-509. PubMed ID: 37015002
[TBL] [Abstract][Full Text] [Related]
37. Beta-2 microglobulin predicts the outcome after autologous stem cell transplantation in non-Hodgkin lymphoma.
Atesoglu EB; Hacıhanefioglu A; Gulbas Z
Transfus Apher Sci; 2015 Feb; 52(1):65-71. PubMed ID: 25577449
[TBL] [Abstract][Full Text] [Related]
38. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
Caballero MD; Rubio V; Rifon J; Heras I; García-Sanz R; Vázquez L; Vidriales B; del Cañizo MC; Corral M; Gonzalez M; León A; Jean-Paul E; Rocha E; Moraleda JM; San Miguel JF
Bone Marrow Transplant; 1997 Sep; 20(6):451-8. PubMed ID: 9313877
[TBL] [Abstract][Full Text] [Related]
39. Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Lee YS; Liu J; Fricano KA; Webb EM; Toolsie DR; Jones S; Rhoads JA; Vij R; Cashen AF; Abboud CN; Westervelt P; Bartlett NL; Dipersio JF; Kreisel FH; Lim KH
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2199-2204. PubMed ID: 28847710
[TBL] [Abstract][Full Text] [Related]
40. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
